- Neurocrine Biosciences has initiated a Phase 2 open-label study of CRENESSITY (crinecerfont) in U.S. children aged 3 months to under 4 years with classic congenital adrenal hyperplasia, alongside reaching target enrollment for a similar early-age trial in the EU, aiming to support a supplemental U.S. filing to extend its current indication.
- This push into very young pediatric patients addresses a group with no approved therapies and could broaden CRENESSITY’s clinical footprint within Neurocrine’s rare-disease franchise.
- We’ll now look at how expanding CRENESSITY into very young children with classic CAH may influence Neurocrine’s broader investment narrative.
The latest GPUs need a type of rare earth metal called Dysprosium and there are only 30 companies in the world exploring or producing it. Find the list for free.
Neurocrine Biosciences Investment Narrative Recap
To own Neurocrine today, you need to be comfortable with a story anchored in INGREZZA cash flows and growing reliance on CRENESSITY to extend the rare‑disease franchise. The new Phase 2 study in very young children with classic CAH is an incremental positive for the CRENESSITY thesis, but it does not change that the key near term catalyst remains commercial execution and payer access for the existing adult and older pediatric label, while pricing and reimbursement pressure on INGREZZA is still the central risk.
The most relevant recent development alongside this CAH news is Neurocrine’s confirmation of 2026 INGREZZA net product sales guidance of US$2,700 million to US$2,800 million. That reminder of how dependent earnings remain on a single movement disorder drug puts the CRENESSITY pediatric expansion into context: successful label broadening may help diversify revenue over time, but it also raises questions about future payer scrutiny and access hurdles across both franchises.
Yet beneath the strong growth story, investors should be aware that rising regulatory and payer scrutiny could eventually lead to tougher reimbursement terms for CRENESSITY and INGREZZA...
Read the full narrative on Neurocrine Biosciences (it's free!)
Neurocrine Biosciences' narrative projects $5.1 billion revenue and $1.5 billion earnings by 2029. This requires 18.0% yearly revenue growth and roughly an $831.4 million earnings increase from $668.6 million today.
Uncover how Neurocrine Biosciences' forecasts yield a $192.88 fair value, a 7% upside to its current price.
Exploring Other Perspectives
More bullish analysts were already assuming revenue could reach about US$6.4 billion and earnings US$2.7 billion, which is far more optimistic than consensus and places even greater weight on CRENESSITY’s rare disease expansion holding up against tougher future reimbursement scrutiny.
Explore 3 other fair value estimates on Neurocrine Biosciences - why the stock might be worth just $192.88!
Decide For Yourself
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Neurocrine Biosciences research is our analysis highlighting 3 key rewards that could impact your investment decision.
- Our free Neurocrine Biosciences research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Neurocrine Biosciences' overall financial health at a glance.
No Opportunity In Neurocrine Biosciences?
Our top stock finds are flying under the radar-for now. Get in early:
- Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
- The future of work is here. Discover the 31 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
- We've uncovered the 9 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com